SOX2 and small cell lung carcinoma: This finding aligns with previous research linking MCAM expression to chemoresistance in small-cell lung cancer (SCLC), in which authors also noted its correlation with a mesenchymal phenotype, and discussed its possible involvement in EMT, considering that PI3K/AKT/SOX2 is a well-described EMT-regulating pathway [132].